Fennec Pharmaceuticals Inc. (OTCMKTS:FENCF) Files An 8-K Material Modification to Rights of Security Holders
Item 3.03
|
Material Modification to Rights of Security Holders |
On November 15, 2016, Fennec Pharmaceuticals Inc. (the Company or
Fennec), announced its board of directors approved an amendment
to the exercise price of 366,133 common share purchase warrants
originally issued on December 3, 2014 from USD$3.60 to USD$2.50
(the Amendment). No other changes will be made to the terms of
the Warrants, and the Warrants expire on December 3, 2016.
The Warrants were issued in connection with a previous financing
of the Company and the holders are arms length to the Company.
The Amendment will become effective on November 29, 2016, being
10 business days after the date of this press release.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit No. | Description | |
| Exhibit 99.1 | Press Release dated November 15, 2016 |
About Fennec Pharmaceuticals Inc. (OTCMKTS:FENCF)
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors. Fennec Pharmaceuticals Inc. (OTCMKTS:FENCF) Recent Trading Information
Fennec Pharmaceuticals Inc. (OTCMKTS:FENCF) closed its last trading session 00.00 at 1.84 with 200 shares trading hands.
